PSA screening for prostate cancer: Why so much controversy?

Asian Journal of Andrology

Volumn 15, Issue 5, 2013, Pages 603-607

  Labrie, Fernand ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Early diagnosis; Improved survival prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HUMAN; MEDICAL PRACTICE; PATIENT CARE; PATIENT DECISION MAKING; PHYSICIAN; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

AGED; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84883471786     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2013.70     Document Type: Review

References (29)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30
2. US Preventive Services Task Force. Screening for prostate cancer: Draft recommentation statement. Rockville, MD: US Preventive Services Task Force; 2001. http://www. uspreventiveservicestaskforceorg/uspstf12/prostate/ draftrecprostate.htm
3. Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-Term control or possible cure of localized prostate cancer? Urology 2002; 60: 115-9
4. Labrie F. Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 2011; 8: 73-85
5. Labrie F, Dupont A, Bélanger A, Giguère M, Lacourcière Y et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival. J. Steroid Biochem 1985; 23: 833-41
6. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24
7. Denis LJ, Keuppens F, Smith PH, Whelan P, Carneiro de Moura JL et al. Maximal androgen blockade: Final analysis of EORTC Phase III trial 30853. Eur Urol 1998; 33: 144-51
8. Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S et al. The case for androgen deprivation as primary therapy for early stage disease: Results from J-CaP and CaPSURE. J Urol 2006; 176: S47-9
9. Ueno S, Namiki M, Fukagai T, Ehara H, Usami M et al. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: A retrospective multicenter study. Int J Urol 2006; 13: 1494-500
10. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M et al. Serum prostate specific antigen (PSA) as prescreening test for prostate cancer. J Urol 1992; 147: 846-52
11. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL et al. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83-91
12. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-90
13. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L et al. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713-9
14. Labrie F, Cusan L, Gomez JL, Bélanger A, Brousseau G et al. Screening decreases prostate cancer mortality: 11-year follow-up on the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311-8
15. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125-32
16. Andriole GL, Grubb RL 3rd, Buys SS, Chia D, Church TR et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
17. Howard DH. Declines in prostate cancer incidence after changes in screening recommendations. Arch Intern Med 2012; 172: 1267-8
18. Scosyrev E, Wu G, Mohile S, Messing EM. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: Analysis of trends over time. Cancer 2012; 118: 5768-76
19. Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 2010; 7: 303-11
20. Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S et al. Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam). Int J Cancer 2010; 127: 2639-44
21. Crawford ED, Grubb R 3rd, Black A, Andriole GL Jr, Chen MH et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011; 29: 355-61
22. D'Amico AV. Prostate-cancer mortality after PSA screening.N Engl J Med 2012; 366: 2229
23. Candas B, Labrie F, Gomez JL, Cusan L, Chevrette E et al. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol 2006; 175: 510-6; discussion 516-7
24. Labrie F, Candas B, Cusan L, Gomez JL, Diamond P et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996; 47: 212-7
25. de Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH et al. Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002; 98: 268-73
26. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
27. US Preventive Services Task Force. Screening for prostate cancer. U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 185-91
28. Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among U.S. men: Findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008; 17: 636-44
29. Huggins C, Hodges CV. Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-307